AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01412879
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01412879
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO or IV
Trial: NCT01412879
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02109029
Drug: Insulin Peglispro
RxNorm normalized name: Insulin peglispro
DrugBank: Insulin peglispro (DB11567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT02109029
Drug: Human Insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT03332069
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03184870
Drug: BMS-813160
RxNorm normalized name: BMS-813160
DrugBank: BMS-813160 (DB16240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT03184870
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT03184870
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT03184870
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT03184870
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT00059657
Drug: Ecraprost in lipid emulsion
RxNorm normalized name: propofol lipid emulsion
DrugBank: Ecraprost (DB16148)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00476138
Drug: Epigallocatechin-gallate
DrugBank: Epigallocatechin gallate (DB12116)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01538771
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa 300ug intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning and conventional treatment
Trial: NCT04101890
Drug: Diaper care with Theraworx
RxNorm normalized name: Vanicream Diaper Rash
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theraworx foam formulation to be used as a preventive and treatment agent for diaper rashes
Trial: NCT03368859
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous
Trial: NCT03368859
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous
Trial: NCT03397186
Drug: Trabectedin
RxNorm normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given as standard of care
Trial: NCT02354833
Drug: Phenylephrine
RxNorm normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00112476
Drug: bryostatin 1
RxNorm normalized name: Bryostatin 1
DrugBank: Bryostatin 1 (DB11752)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00112476
Drug: temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT00345605
Drug: Sodium Phenylbutyrate
RxNorm normalized name: Sodium Phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: None will be administered during the washout period; 500 mg/kg/day or 10 grams/m2 will be administered during the first one week treatment period in addition to arginine
Trial: NCT03601897
Drug: Rebastinib
RxNorm normalized name: Rebastinib
DrugBank: Rebastinib (DB13005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT03601897
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel administered by IV infusion at 80 mg/m\^2
Trial: NCT03518554
Drug: JAB-3068
RxNorm normalized name: JAB-3068
DrugBank: JAB-3068 (DB17131)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JAB-3068 will be orally administered on a daily basis. Patients need to fast 2 hours before （6 hours for PK days) and 2 hours after each dosing.
Trial: NCT02210780
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered via subcutaneous injection.
Trial: NCT00003956
Drug: lonafarnib
RxNorm normalized name: LONAFARNIB
DrugBank: Lonafarnib (DB06448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01689558
Drug: Recombine Endostatin
RxNorm normalized name: Recombinant human endostatin
DrugBank: Endostatin (DB06423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombine Endostatin is involved in the arm of Recombine Endostatin .Recombinant human vascular endothelial inhibin 7.5 mg/M2 / d dose add 250 ml of physiological saline, dilute in new adjuvant chemotherapy began to 8-21 days intravenous drip, at least 1 hour, a total of 1 cycle; The chemoradiation in cisplatin chemotherapy first day grace degrees 7.5 mg/M2 / d, 1-14 days, a total of one period of treatment
Trial: NCT03542838
Drug: Resiniferatoxin
RxNorm normalized name: resiniferatoxin
DrugBank: Resiniferatoxin (DB06515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resiniferatoxin is a compound purified from natural sources.
Trial: NCT03542838
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline is a normal physiological solution
Trial: NCT00428168
Drug: Betahistine
RxNorm normalized name: betahistine
DrugBank: Betahistine (DB06698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine 24mg BID
Trial: NCT00004255
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004255
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004255
Drug: tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02966314
Drug: Omalizumab
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Omalizumab 300mg subcutaneous injection once monthly for 6 months. Total dose will be divided into two 150mg/1.2mL injections.
Trial: NCT00054470
Drug: tipifarnib
RxNorm normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03849729
Drug: Phentermine
RxNorm normalized name: Phentermine
DrugBank: Phentermine (DB00191)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is a randomized, control trial to investigate the effect and safety of Phentermine in patients with obesity who need a bariatric surgery (BMI \>35 kg/m2 with comorbidities or BMI \> 40 kg/m2).
Trial: NCT01287754
Drug: erlotinib [Tarceva]
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg daily orally
Trial: NCT00928915
Drug: Prothrombin complex concentrate (PCC); fresh frozen plasma (FFP)
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous, repeated until INR ≤ 1.2
Trial: NCT03754049
Drug: DSP
RxNorm normalized name: DSP107
DrugBank: DSP107 (DB17501)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone sodium phosphate (DSP) is a glucocorticoid widely used in the treatment of joint pain such as gout, osteoarthritis and rheumatoid arthritis via IA injection.
Trial: NCT04122196
Drug: Pregabalin 300mg
RxNorm normalized name: PREGABALIN 300MG CAP,ORAL
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patient will receive a compounded version of 300mg pregabalin PO approximately one hour before surgery.
Trial: NCT00492986
Drug: Nexavar (Sorafenib, BAY43-9006)
RxNorm normalized name: Nexavar
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multikinase inhibitor: Sorafenib mono therapy 400 mg bid
Trial: NCT01328379
Drug: Dalfampridine-ER 5mg
RxNorm normalized name: dalfampridine Extended Release Oral Tablet
DrugBank: Dalfampridine (DB06637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg, twice daily
Trial: NCT01328379
Drug: Dalfampridine-ER 10mg
RxNorm normalized name: dalfampridine Extended Release Oral Tablet
DrugBank: Dalfampridine (DB06637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg, twice daily
Trial: NCT00000378
Drug: Sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 week trial dose up to 200mgs
Trial: NCT00000378
Drug: Nortriptyline
RxNorm normalized name: Nortriptyline
DrugBank: Nortriptyline (DB00540)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 week trial dose adjusted to therapeutic level
Trial: NCT00803556
Drug: Alvespimycin
RxNorm normalized name: Alvespimycin
DrugBank: Alvespimycin (DB12442)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution, IV, 60-100 mg/m2, weekly until disease progression or DLT
Trial: NCT00803556
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Solution, IV, 2-4 mg/kg, weekly until disease progression or DLT
Trial: NCT00803556
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Solution, IV, 60-90 mg/m2, weekly until disease progression or DLT
Trial: NCT01929083
Drug: Progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
Trial: NCT01929083
Drug: Ibutilide
RxNorm normalized name: Ibutilide
DrugBank: Ibutilide (DB00308)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ibutilide 0.003 mg/kg administered to all subjects to moderately lengthen the QT interval
Trial: NCT00644592
Drug: Fenofibrate capsule daily for 4 weeks
RxNorm normalized name: Fenofibrate Capsules
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo capsule daily for 4 weeks
Trial: NCT00644592
Drug: Fenofibrate
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 160 mg/day orally for 4 weeks
Trial: NCT04390685
Drug: Tacrolimus ointment
RxNorm normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment with tacrolimus ointment once daily for one year following axillary lymph node dissection
Trial: NCT01075087
Drug: (study group) will receive a bilateral TAP block using 20 cc of 0.5% ropivacaine on each side.
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (study group) will receive a bilateral TAP block using 20 cc of 0.5% ropivacaine on each side.
Trial: NCT00235521
Drug: aerosolized iloprost
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01049776
Drug: Pazopanib (GW786034)
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pazopanib 800 mg daily x 12 weeks, (Cycle = 21 days) up to 24 months
Trial: NCT02113657
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3 mg/kg by vein once every 3 weeks for a total of 4 doses.
Trial: NCT04328480
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The colchicine dosage schedule will vary according to the following scenarios:~1. In patients not receiving Lopinavir/Ritonavir~   * Loading dose of 1.5 mg followed by 0.5 mg after two hours (day 1)~  * The next day 0.5 mg bid for 14 days or until discharge.~2. In patients receiving Lopinavir/Ritonavir~   * Loading dose of 0.5 mg (day 1)~  * After 72 hours from the loading dose, 0.5 mg every 72 hours for 14 days or until discharge.~3. Patients under treatment with Colchicine that are starting with Lopinavir/Ritonavir~   * Dose of 0.5 mg 72 hours after starting Lopinavir/Ritonavir.~  * Continue with 0.5 mg every 72 hours for 14 days or until discharge.~Only the oral route will be used except in the case of patients associated with mechanical ventilation or with contraindications to the oral route, in whom it will be administered by nasogastric tube.
Trial: NCT01829048
Drug: PF-02545920
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg (2 mg X 2d, 5 mg X 2d, 8 mg X 3 d, then 15 mg) Q12h
Trial: NCT01829048
Drug: PF-02545920
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg (5 mg X 2d, 10 mg X 2d, then 15 mg) Q12h
Trial: NCT01829048
Drug: PF-02545920
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg (5 mg BID for 7 days 10 mg BID for 7 days, then 15 mg BID for 4 days) Q12h
Trial: NCT02561156
Drug: TAK-653 Placebo
RxNorm normalized name: TAK-653
DrugBank: TAK-653 (DB16304)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-653 placebo-matching tablets.
Trial: NCT02561156
Drug: TAK-653
RxNorm normalized name: TAK-653
DrugBank: TAK-653 (DB16304)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-653 tablets.
Trial: NCT01241539
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg capsule
Trial: NCT01241539
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg capsule
Trial: NCT01241539
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 110 mg capsule
Trial: NCT01606462
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intranasal administration, 24 IU oxytocin; ; 3 puffs per nostril, each with 4 IU OXT
Trial: NCT01937312
Drug: Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01549990
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: maintenance of general anesthesia with sevoflurane
Trial: NCT01549990
Drug: desflurane
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: maintenance of general anesthesia with desflurane
Trial: NCT02832089
Drug: oral carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral carvedilol in escalating doses for reducing ventricular rate in AF patients
Trial: NCT03723447
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine will be given during the bilateral laparoscopic-guided TAP block given to each patient intraoperatively.
Trial: NCT01175512
Drug: Naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 days, counterbalanced dosing of 25mg, 50mg, placebo, placebo.
Trial: NCT02252367
Drug: Tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tadalafil 5 mg once daily for 12 weeks.
Trial: NCT01504503
Drug: Donepezil Hydrochloride
RxNorm normalized name: Donepezil Hydrochloride
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil Hydrochloride Tablets 10 mg
Trial: NCT01504503
Drug: Aricept
RxNorm normalized name: Aricept
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aricept 10 mg Tablets
Trial: NCT04460430
Drug: Neratinib + endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Neratinib plus Fulvestrant, Exemestane or Tamoxifen
Trial: NCT03401749
Drug: Chlorhexidine Gluconate 2% Wipe
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 2% WIPE
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be instructed to use CHG wipes after showering the night before surgery and again on the morning of surgery.
Trial: NCT01916577
Drug: Plerixafor mobilization of autologous CD117 stem cells
RxNorm normalized name: Longeveron mesenchymal stem cells
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peripheral mobilization of autologous CD117+ stem cells from the bone marrow in patients awaiting lung transplantation versus normal controls
Trial: NCT00312520
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01307423
Drug: Apremilast 20mg
RxNorm normalized name: APREMILAST 20MG ORAL TAB
DrugBank: Apremilast (DB05676)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Apremilast 20mg twice daily, orally
Trial: NCT01307423
Drug: Apremilast 30mg
RxNorm normalized name: APREMILAST 30MG TAB
DrugBank: Apremilast (DB05676)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Apremilast 30mg twice daily, orally
Trial: NCT02886429
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound guided paravertebral block with bupivacaine
Trial: NCT02886429
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ultrasound guided paravertebral block with dexmedetomidine
Trial: NCT00134914
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: single doses given by sublingual and parenteral routes
Trial: NCT00942006
Drug: ceftriaxone
RxNorm normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2g x 1 iv, 14 days
Trial: NCT02213718
Drug: Desflurane
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: desflurane (7%-8% end-tidal concentration)
Trial: NCT02213718
Drug: propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: propofol (TCI:3.5-4.0μg/min)
Trial: NCT04425655
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg/m2 days 1 through 5
Trial: NCT04425655
Drug: Vyxeos
RxNorm normalized name: Vyxeos
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100U/m2 days 1, 3 5 in induction, 65U/m2 days 1 and 3 for consolidation
Trial: NCT02970773
Drug: Rivaroxaban Oral Tablet
RxNorm normalized name: rivaroxaban Oral Tablet
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral application of Xarelto
Trial: NCT01497392
Drug: dovitinib lactate
RxNorm normalized name: Dovitinib
DrugBank: Dovitinib (DB05928)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01497392
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02687269
Drug: Ranolazine
RxNorm normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in this arm receive Ranolazine at a dose of 375 mg twice daily in the three days before surgery
Trial: NCT04438421
Drug: Filming mouthwash formulation, enriched with Hydrogen Peroxide and Hyaluronic Acid
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will then be given the test product, BMG0703, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
Trial: NCT04438421
Drug: Chlorhexidine mouthwash
RxNorm normalized name: chlorhexidine Mouthwash
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will then be given Chlorhexidine 0.2%mouthwash, as an active comparator, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
Trial: NCT00318955
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00318955
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01400646
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Type=exact number, unit=mg, number=20, form=tablet, route=oral use. One tablet once daily for 5 days (Treatment Period 1, Days 1-7).
Trial: NCT01400646
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Type=exact number, unit mg, number=10, form=tablet , route=oral use. One tablet for 2-4 days (Treatment Period 1, Day 6 up to Day 11).